Tenax Therapeutics Inc (TENX NASDAQ) stock market data APIs
$1.8008
-0.04(-2.2%)
as of August 14, 2026
Try our APIs with
free plan!
Tenax Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Prev. Close
1.8008
Open
1.7617
High
1.8678
Low
1.707
52 wk Range
1.31-19.4
Market Cap
67 363 K
Shares Outstanding
37 424 K
EPS
-0.35
Beta
0.933
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Tenax Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at €19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
Get Tenax Therapeutics Inc data using free add-ons & libraries
Get Tenax Therapeutics Inc Fundamental Data
Tenax Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -19 486 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
€
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-31
- EPS/Forecast: -0.38
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tenax Therapeutics Inc News
New
Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout
Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inf...
Tenax Posts Wider Q2 Loss; Phase 3 Heart Drug Results Due In August
(RTTNews) - Tenex Therapeutics (TENX) on Friday reported second-quarter results, reflecting a wider net loss for the quarter ended June 30, 2026. Company Profile Tenax Therapeutics is a clinical-sta...
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or ...
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutic...
Get Tenax Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
€19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only €19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
€99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
